Our lab showed in the past that in Gaucher disease (GD), resulting from accumulation of glucosylceramides due to mutations in the GBA1 gene, encoding acid-β-glucocerebrosidase (GCase), the mutant variants are retained in the ER and activate the UPR [3,4,5,6,7,8]. This evidence concerns the gene GBA1 and Gaucher disease.